147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension

New FDA Approvals

147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension - New FDA Approvals